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Summary DBA/2NCrIBR Fl mice received a single i.v. injection of doxorubicin (4.32, 7.20 or
12.00mgkg-'), cyclophosphamide (70, 120 or 200mgkg-1) or cis-diamminechloroplatinum (5.4, 9.0 or
15.0mgkg-'), alone or 2h before an i.p. injection of 1,000mgkg-' of diethyldithiocarbamate (DDTC).
Twenty-four hours after, survival of bone marrow colony forming units-spleen and granulocyte-macrophage
colony forming cells, was determined. On the whole, administration of DDTC reduced the toxic effect of the
three anticancer drugs on haemopoietic progenitors. The effect was in general more evident at the lower than
at the higher doses of the antitumour drugs.
Among drugs that protect against toxicity of antineoplastic
agents, thiocompounds are receiving ever increasing
attention. As a result of their intrinsic selectivity of action or
following administration at an appropriate time with respect
to the antitumour drug or in separate body compartments
(Howell et al., 1983), the protective effects of selected thiols
on normal tissues seem to be unaccompanied by
concomitant protection on tumour cells (Yuhas & Culo,
1980; Borch et al., 1980; Brock & Pohl, 1983; Meinstrich et
al., 1984; Bodenner et al., 1986a, b). In experimental studies,
renal, gastrointestinal and general toxicity of cis-diammine-
dichloroplatinum (cis-DDP), cardiotoxicity of doxorubicin
(DX) and general and bladder toxicity of cyclophosphamide
(CY) were reduced by administration of diethyldithio-
carbamate (DDTC), sodium thiosulphate, n-acetyl-cysteine,
mesna and WR2721 (Yuhas & Culo, 1980; Brock & Pohl,
1980; Meinstrich et al., 1984; Borch & Pleasants, 1979;
Bodenner et al., 1986a, b; Howell & Taettle, 1983; Doroshow
et al., 1981; Glover et al., 1984; Allan et al., 1986).
Studies on the effects of thiocompounds on bone marrow
toxicity, which is a major dose-limiting effect of most
anticancer drugs, have given contrasting results. In vivo
DDTC and WR2721 afford protection against cis-DDP and
CY toxicity on mice bone marrow haemopoietic progenitors
and peripheral blood leukocytes in mice (Brock & Pohl,
1983; Yuhas et al., 1980; Wasserman et al., 1981; Gringeri &
Borch, 1984). In vitro, sodium thiosulphate reduces the
toxicity of cis-DDP on mice bone marrow granulocyte-
macrophage colony forming cells (GM-CFC) (Howell &
Taetle, 1980). In contrast, mesna had no protective effect on
mice bone marrow colony forming units spleen (CFU-S)
against CY toxicity (Millar et al., 1983), and in our previous
experiences no effect of n-acetylcysteine, on pluripotent and
committed haemopoietic stem cells of mice treated with CY,
DX or cis-DDP was found (Massa et al., 1985; Lerza et al.,
1986).
The present study was carried out to determine whether
DDTC could reduce DX, CY or cis-DDP toxicity on murine
pluripotent (CFU-S) and committed (GM-CFC)
haemopoietic stem cells. The anticancer drugs were selected
for their clinical relevance and because, according to the
above-cited studies, one or more of their toxic effects were
reduced by administration of thiocompounds. DDTC is
related to disulphiram, a thiocompound which has long been
used in the clinical setting, and has itself been clinically
applied in cases of acute nickel-carbonyl poisoning
(Sunderman, 1971). According to previous studies (Brock &
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Pohl, 1983; Evans et al., 1984; Gale et al., 1982;
Khanderkar, 1983), DDTC protects against renal, gastro-
intestinal and bone marrow toxicity of cis-DDP and in
appropriate treatment conditions it does not inhibit the
antitumour effect of cis-DDP. The fact that uptake of 35S-
labelled DDTC is greater in kidney, lung and bone marrow
than in tumour tissue (Evans et al., 1983) may partially
explain the selectivity of action of the thiol compound. It
appears worthwhile to ascertain whether DDTC affords
protection to the haemopoietic progenitor cells against
anticancer drugs other than cis-DDP.
Materials and methods
Research animals
Experiments were carried out on 2- to 3-month-old DBA/
2NCr1BR Fl mice of both sexes obtained from Charles
River (Como, Italy). The mice were normally bred and
maintained in a conventional environment with pellet food
and water ad libitum. For the transplant method of CFUs
assay, recipient mice were irradiated with a Theratron Junior
cobalt 60 unit (0.8 Gymin-1; total dose delivered 9Gy).
Drugs
DX (Adriblastina, Farmitalia-Carlo Erba, Milano Nerviano,
Italy), CY (Endoxan Asta, Schering) and cis-DDP (Platinex,
Bristol) were dissolved in sterile saline. Each dose was i.v.
injected as 0.5 ml of the appropriate dilution. DDTC
(sodium salt obtained from Sigma Chemical Company) was
dissolved in sterile saline. The selected i.p. dose was
administered in a volume of 0.5 ml.
Experimental design
The aim of the experiment was to allow a comparison
between the effect of haemopoietic progenitors of anticancer
drugs given alone and that of the same drugs followed 2 h
later by DDTC. In situ survival of p.b. leukocytes, bone
marrow CFU-S and GM-CFC was determined 24 h after
administration of drug increasing doses of the drug. Mice
were randomly divided into groups of five animals. One
group received an i.p. injection of 1,000mgkg-1 of DDTC.
According to the Registry of Toxic Effects of Chemical
Substances 1981/2 (Tatken & Lewis, 1981/2), the LD50 for
i.p. DDTC in mice is 1,500mgkg-1. A 1,000mgkg-I i.p.
dose of DDTC was found to afford maximal protection
against cis-DDP general toxicity in previous experiences on
mice (Evans et al., 1984). I.p. injection was preferred to i.v.
administration since the latter seems to favour delivery of
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DDTC to the kidney (Borch et al., 1980). The other groups
received a single i.v. injection of DX, CY or cis-DDP. Each
anticancer drug was tested at three dose levels, whose range
was selected on the basis of preliminary research on lethal
effects of the drugs on the adopted strain of mice. LD50 at
21 days was 12, 200 and 15 mgkg-1 body weight
respectively for DX, CY and cis-DDP. The doses adopted
were as follows: DX 4.32, 7.20 and 12.00mgkg-1 body
weight; CY 70, 120 and 200mgkg-1; cis-DDP 5.4, 9.0 and
15.0 mgkg-1. The remaining groups received a single i.v.
dose of anticancer drug and 2 h later an i.p. administration
of 1,000mgkg- 1 of DDTC. Scheduling of DDTC at 2 h
after the anticancer drug administration was based on results
obtained by Bodenner et al. (1986a, b) on protection against
cis-DDP toxicity by DDTC. Twenty-four hours after anti-
cancer treatment (22 h after DDTC administration in the
first group), under slight ether anaesthesia, mice were killed
by cervical dislocation. Both femurs were removed and bone
marrow suspensions were prepared. Bone marrow
concentration of CFU-S and GM-CFC was determined (see
below).
Methods
Bone marrow collection, preparation of bone marrow mono-
dispersed cell suspensions and estimation of bone marrow
cellularity were performed with the usual methods. A first
aliquot of the bone marrow cell suspension was assayed for
CFU-S content by the transplant method (Till & McCulloch,
1961). An aliquot of 0.5 ml of bone marrow cell suspension,
diluted to contain 4 x 104 marrow cells, was injected into
tail veins of nine recipient mice. Nine days after injection the
host mice were killed under slight ether anaesthesia and their
spleens were excised and fixed. The number of visible
colonies was then counted, and the total number of CFU-S
per femur (±standard error) was determined from the mean
of the counts. To assay GM-CFC (Bradley & Metcalf, 1966),
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1 ml of agar medium containing 1 x 105 bone marrow cells
and 20% horse serum was pipetted into triplicate 35 mm
Falcon Petri dishes over 0.1 ml of a colony-stimulating factor
obtained from mice treated with endotoxin from Salmonella
typhosa.
The number of colonies containing more than 50 cells was
recorded after 7 days of incubation and the mean number of
GM-CFC per femur (±s.e.m.) was determined. Additional
technical details can be found in a previous publication
(Pannacciulli et al., 1982). Normal values (±s.e.m.) in a
group of untreated mice were bone marrow GM-CFC
11,375 + 1,187 per femur; bone marrow CFU-S 4,062 + 318
per femur. To prevent possible day-to-day variations in the
assays, single data points obtained in treated mice and in
controls were determined on the same day. The contents of
CFU-S and GM-CFC per femur were normalised to those
found in saline-treated controls. Student's t test was used for
statistical comparison between the experimental groups.
Results
Effect of DDTC in a single 1,000mgkg-' injection on bone
marrow CFU-S and GM-CFC
The DDTC injection did not modify bone marrow or
progenitor counts determined at 22 h after administration of
the drug. At that time values in DDTC treated mice were
bone marrow GM-CFC 11,190 + 1,451 colonies per femur;
bone marrow CFU-S 3,974 + 366 colonies per femur. These
values were not significantly different from those found in
control mice (for each tested value P<0.01).
Survival of bone marrow CFU-S and GM-CFC in mice 24h
after DX or DX plus DDTC administration
Following increasing DX doses, survival of all tested popula-
tions decreased significantly (Figure 1). Administration of
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Figure 1 Survival of bone marrow GM-CFC and CFU-S 24h after DX (1) or DX plus DDTC (L]) single injection (values are
mg per kg body weight). For each experimental point vertical bars are men ± s.e.m. * Significantly different (P<0.01).
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Figure 2 Survival of bone marrow GM-CFC and CFU-S 24h after CY (0) or CY plus DDTC (El) single injection (values are
mg per kg body weight). For each experimental point vertical bars are mean s.e.m. * Significantly different (P<0.01).
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Figure 3 Survival of bone marrow GM-CFC and CFU-3 24h after cis-DDP (0) or cis-DDP plus DDTC (El) single injection
(values are mg per kg body weight). For each experimental point vertical bars are mean + s.e.m. * Significantly different (P<0.01).
DDTC 2 h after DX reduced the toxic effect of the latter on
bone marrow CFU-S and CFC-C. Survival of CFU-S after
the two lower doses of DX and that of GM-CFC following
all doses of the anticancer drug were significantly higher
than in controls. The protective effect of DDTC on GM-
CFC was particularly striking.
Survival of bone marrow CFU-S and GM-CFC in mice 24h
after CY or CY plus DDTC administration
Following administration of increasing doses of CY survival
of tested population resulted significantly decreased
(P<0.01) (Figure 2). DDTC administered 2 h after CY
increased survival of bone marrow GM-CFC at the lowest
CY dose and that of bone marrow CFU-S following the two
higher doses of the anticancer drug. Following the lowest
CY dose CFU-S survival was higher in DDTC treated mice
but the difference was not statistically significative.
Survival of bone marrow CFU-S and GM-CFC in mice 24h
after cis-DDP or cis-DDP plus DDTC administration
At every tested dose, cis-DDP caused a significant reduction
in bone marrow CFU-S and GM-CFC (Figure 3). GM-CFC
appeared to be more sensitive to cis-DDP than CFU-S. At
cis-DDP doses of 5.4 and 9mgkg-1, survival of GM-CFC
and of CFU-S was significantly (P<0.01) higher after cis-
DDP plus DDTC than after cis-DDP alone. Following the
15mgkg-1 dose of cis-DDP, DDTC afforded no protection
to these populations.
Discussion
Results here reported show that, on the whole, DDTC is
able to reduce toxicity of cis-DDP, DX and CY on haemo-
poietic progenitors. Its effect is in general more evident
following the lower dose of the drugs but, in the case of
toxicity on bone marrow GM-CFC of DX and on bone
marrow CFU-S of CY, the protective effect is extended to
the higher doses of both drugs.
This lack of correlation between CFU-S and GM-CFC
response may be explained by the different kinetics of the
tested population. In normal mice the former population has
low proliferative activity while committed progenitors are
actively proliferating.
Considering the interval (2 h) between anticancer drug
administration and DDTC injection and plasma clearance
half-times of DX (Formelli et al., 1985), CY (Mellet, 1969)
and cis-DDP (Brock & Pohl, 1983; Evans et al., 1984) in
mice, the antitumour drugs probably reach target sites before
DDTC administration. Thus the latter possibly operates
interfering with the anticancer drug action at a cellular level.
The mechanism of the protective action of DDTC on
haemopoietic progenitor toxicity of anticancer drug is not
clear. DDTC may be able to delete cis-DDP bound to
enzyme sulphydryl groups (Borch & Pleasants, 1979; Daley-
Yates & McBrien, 1982) or to reverse its inactivation of
critical cellular proteins (Gonias et al., 1984). The two
hypotheses take into account the rather peculiar mechanism
of action of cis-DDP, which contains a heavy metal. How-
ever, the protective action of DDTC seems to extend to a
wider range of toxic mechanisms, since the compound can
reduce the sensitivity of bone marrow stem cells to radiation
(Evans et al., 1983) and to antineoplastic compounds other
than cis-DDP, as shown by the results here reported.
DDTC, as other thiol donors, may protect tissues as a
result of interference with free radical reactions (Harris &
Philips, 1971; Yoda et al., 1986). It has been proved that
among anticancer drugs tested in this research, DX forms
free radicals in various cell types and that they have a role in
cardiac toxicity of the drug (Myers, 1982). However, haemo-
toxicity of DX does not seem to be related to free radicals,
and in our experience (Massa et al., 1985), n-acetyl-cysteine
did not appear to induce any consistent decrease in the
toxicity of DX on haemopoietic progenitors. The results of
the present work seem to show that DDTC does have this
effect. The contrasting effects of the two thiol donors may be
explained by the greater efficiency of DDTC as a thiol donor
or by an inappropriate marrow penetration of
n-acetyl-cysteine.
The intrinsic mechanism of the protective effect of DDTC
on haemopoietic stem cells of CY-treated mice is still
obscure as well. Thiol compounds, however, seem to be of
great importance in modulating general cytotoxicity of alky-
lating agents (Ozols & Cowan, 1986; Tomashefsky et al.,
1985). For instance buthionine sulphoximine, an inhibitor of
glutathione synthesis, may increase the toxicity of high doses
of CY in tumour-bearing mice (Dorr et al., 1986) and in the
present work DDTC seemed partially to protect haemopoie-
tic progenitors from the toxic action of CY. In contrast
mesna and n-acetyl-cysteine had no protective effect on
haemopoietic stem cells of mice treated with CY (Millar et
al., 1983; Massa et al., 1985). As is the case with DX, the
efficiency or the pharmacokinetics of DDTC may explain
why it is more active than other thiol donors. The protective
effect of DDTC on bone marrow CFU-S of mice treated
with CY is intriguing considering that in vitro, probably as a
result of the inhibition of aldehyde dehydrogenase activity,
DDTC potentiates the cytotoxic action of 4-hydroperoxy-
cyclophosphamide in the CFU-S assay (Khorn & Sladek,
1984).
In conclusion, it emerges from the present work that
DDTC reduces toxicity of anticancer drugs of different types
on mice haemopoietic progenitors. Lack of parallel studies
on tumour-bearing mice does not allow an assessment of the
possible therapeutic advantages which could be had adding
DDTC to tested cytotoxic drugs in cancer treatment. How-
ever, the results here reported on interaction between DDTC
and DX, CY or cis-DDP at a haemopoietic level may be of
significance. They suggest that this thiol donor merits further
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investigation in order to make a definite assessment of its
selectivity and its possible future clinical exploitation.
This study was supported in part by CNR contract no. 86.00511.44
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